Loading mutual fund details…
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Cumulative Option is an equity scheme managed by ICICI Prudential Mutual Fund. Over rolling three-year windows since inception, investors earned a median compounded return of 22.66%, with the bottom and top quartiles at 17.38% and 26.91% respectively. It has ranked in the top half of its category for 5 of the last 7 reported years. Risk-adjusted return (Sharpe ratio) is 0.00. The total expense ratio is 1.87% on assets of ₹6,669Cr. The fund is currently managed by Dharmesh Kakkad, appointed within the last year.
Lower is better.
| Window | Min | P25 | Median |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Same fund, monthly SIPs over rolling 1/3/5-year windows.
| Scheme | AMC | AUM | TER | 3Y |
|---|
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| P75 |
|---|
| Max |
|---|
| Positive % |
|---|
| 1Y | -13.20% | 3.14% | 17.69% | 41.16% | 65.32% | 79.4% |
| 3Y | 13.44% | 17.38% | 22.66% | 26.91% | 30.95% | 100.0% |
| 5Y | 15.10% | 16.62% | 19.12% | 21.25% | 25.48% | 100.0% |
Each cell is one year. Q1 = top quartile within the AMFI category for that period. Cell label is the last two digits of the year.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
Each row is a back-tested SIP — monthly contribution over the regime's duration, no fees adjustment beyond NAV-baked TER. XIRR is the annualised IRR of those cashflows; Abs return is the absolute cash-on-cash; Max DD is the deepest drawdown experienced mid-investment. Past performance is not indicative of future results.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.
| 5Y |
|---|
| Star |
|---|
| UTI Healthcare Fund - Direct Plan - Growth Option | UTI Mutual Fund | ₹1,144 Cr | 1.36% | +26.82% | +14.83% | 3★ |
| UTI Healthcare Fund - Regular Plan - Growth Option | UTI Mutual Fund | ₹1,144 Cr | 2.30% | +25.58% | +13.65% | 3★ |
| SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH | SBI Mutual Fund | ₹4,323 Cr | 0.92% | +25.57% | +16.27% | 3★ |
| SBI HEALTHCARE OPPORTUNITIES FUND - REGULAR PLAN -GROWTH | SBI Mutual Fund | ₹4,323 Cr | 1.90% | +24.26% | +15.05% | 3★ |
| Mirae Asset Healthcare Fund -Regular Growth | Mirae Asset Mutual Fund | ₹2,939 Cr | 2.04% | +24.16% | +13.98% | 3★ |
| Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth | Aditya Birla Sun Life Mutual Fund | ₹901 Cr | 2.27% | +22.88% | +12.34% | 3★ |
| DSP Healthcare Fund - Direct Plan - Growth | DSP Mutual Fund | ₹3,142 Cr | 0.79% | +22.87% | +15.36% | 3★ |
| Tata India Pharma & Healthcare Fund-Regular Plan-Growth | Tata Mutual Fund | ₹1,325 Cr | 2.21% | +21.66% | +13.09% | 3★ |
| Nippon India Pharma Fund-Growth Plan-Growth Option | Nippon India Mutual Fund | ₹8,365 Cr | 2.32% | +21.43% | +12.39% | 3★ |
| ITI Pharma and Healthcare Fund - Direct Plan - Growth Option | ITI Mutual Fund | ₹230 Cr | 3.11% | +21.39% | — | 3★ |